ConductScience.org, home

Comparison · NCT00450437-55e645ed

Novartis MenACWY Vaccine vs Licensed Meningococcal Vaccine: Number of Participants With at Least One Severe Systemic Reaction, Ages 11 to 55 Years

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Novartis MenACWY Vaccine vs Licensed Meningococcal Vaccine: Number of Participants With at Least One Severe Systemic Reaction, Ages 11 to 55 Years. Trial comparisons, record NCT00450437-55e645ed. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00450437-55e645ed

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.03550.02910.0432wilson
Risk in group 20.02740.01850.0405wilson
Risk difference, group 1 minus group 20.00806-0.006490.0199newcombe hybrid score
Risk ratio, group 1 over group 21.290.8322.01log
Odds ratio, group 1 over group 21.30.8282.06log
Number needed to treat, for one more participant with the outcome on Novartis MenACWY Vaccine than on Licensed Meningococcal Vaccine124from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Novartis MenACWY VaccineOne dose of the meningococcal ACWY (three lots combined)conjugate vaccine was administered intramuscularly.942,649OG000
Group 2Licensed Meningococcal VaccineOne dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.24875OG001

Outcome

Type
PRIMARY
Title
Number of Participants With at Least One Severe Systemic Reaction, Ages 11 to 55 Years
Description
Safety of Novartis Meningococcal ACWY and of a licensed meningococcal ACWY conjugate vaccine as measured by the number of participants presenting at least one severe systemic reaction during the first 7 days (Days 1-7) following a single vaccination.~Note: severe adverse events: unable to perform normal daily activity
Time frame
6 days after vaccination
Population
The analysis was performed on the safety set.

Source ClinicalTrials.gov

Trial

Title
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
NCT number
NCT00450437
Phases
PHASE3
Conditions
Meningococcal Infections, Meningococcal Meningitis
Interventions
MenACWY CRM, Meningococcal ACWY Conjugate vaccine
Lead sponsor
Novartis Vaccines
Results first posted
2010-09-24

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00450437-55e645ed